GE-2270A

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
GE-2270A
Accession Number
DB02975  (EXPT01578)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • Antibiotic GE 2270A
External IDs
GE 2270 A / GE-2270 A / GE2270A / MDL-62879
Categories
UNII
JB4J58L2K1
CAS number
134861-34-0
Weight
Average: 1290.51
Monoisotopic: 1289.258060075
Chemical Formula
C56H55N15O10S6
InChI Key
JMDULECOHIXMNX-MZHFYNGJSA-N
InChI
InChI=1S/C56H55N15O10S6/c1-24(2)39-55-70-42(36(87-55)19-80-5)47(77)59-17-38(73)67-43(44(74)26-10-7-6-8-11-26)54-66-34(23-85-54)52-63-31(20-83-52)41-27(50-64-32(21-82-50)46(76)61-29(16-37(72)58-4)53-69-40(25(3)86-53)48(78)68-39)13-14-28(60-41)51-65-33(22-84-51)49-62-30(18-81-49)56(79)71-15-9-12-35(71)45(57)75/h6-8,10-11,13-14,20-24,29-30,35,39,43-44,74H,9,12,15-19H2,1-5H3,(H2,57,75)(H,58,72)(H,59,77)(H,61,76)(H,67,73)(H,68,78)/t29-,30-,35-,39-,43-,44-/m0/s1
IUPAC Name
(2S)-1-[(4S)-2-{2-[(18S,25S,35S)-16,23,30,33-tetrahydroxy-35-[(S)-hydroxy(phenyl)methyl]-28-(methoxymethyl)-21-methyl-18-[(methyl-C-hydroxycarbonimidoyl)methyl]-25-(propan-2-yl)-3,13,20,27,37-pentathia-7,17,24,31,34,39,40,41,42,43-decaazaheptacyclo[34.2.1.1^{2,5}.1^{12,15}.1^{19,22}.1^{26,29}.0^{6,11}]tritetraconta-1(38),2(43),4,6(11),7,9,12(42),14,16,19(41),21,23,26(40),28,30,33,36(39)-heptadecaen-8-yl]-1,3-thiazol-4-yl}-4,5-dihydro-1,3-oxazole-4-carbonyl]pyrrolidine-2-carboximidic acid
SMILES
[H][C@](O)(C1=CC=CC=C1)[C@]1([H])N=C(O)CN=C(O)C2=C(COC)SC(=N2)[C@@]([H])(N=C(O)C2=C(C)SC(=N2)[C@]([H])(CC(O)=NC)N=C(O)C2=CSC(=N2)C2=C(N=C(C=C2)C2=NC(=CS2)C2=N[C@@]([H])(CO2)C(=O)N2CCC[C@@]2([H])C(O)=N)C2=CSC(=N2)C2=CSC1=N2)C(C)C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UElongation factor TuNot AvailableShigella flexneri
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when GE-2270A is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when GE-2270A is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when GE-2270A is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when GE-2270A is combined with Acenocoumarol.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with GE-2270A.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with GE-2270A.
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with GE-2270A.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with GE-2270A.
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with GE-2270A.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with GE-2270A.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C12068
PubChem Compound
16186054
PubChem Substance
46508431
ChemSpider
17314948
ChEBI
29584
ChEMBL
CHEMBL1766417
HET
GEA

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00897 mg/mLALOGPS
logP4.65ALOGPS
logP4.87ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)-2.4ChemAxon
pKa (Strongest Basic)12.01ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count23ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area368.62 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity364.03 m3·mol-1ChemAxon
Polarizability129.25 Å3ChemAxon
Number of Rings11ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.6079
Blood Brain Barrier-0.9933
Caco-2 permeable-0.7018
P-glycoprotein substrateSubstrate0.9014
P-glycoprotein inhibitor IInhibitor0.5257
P-glycoprotein inhibitor IINon-inhibitor0.7343
Renal organic cation transporterNon-inhibitor0.7644
CYP450 2C9 substrateNon-substrate0.7775
CYP450 2D6 substrateNon-substrate0.7616
CYP450 3A4 substrateSubstrate0.6618
CYP450 1A2 substrateNon-inhibitor0.8099
CYP450 2C9 inhibitorNon-inhibitor0.7918
CYP450 2D6 inhibitorNon-inhibitor0.8555
CYP450 2C19 inhibitorNon-inhibitor0.8015
CYP450 3A4 inhibitorNon-inhibitor0.8462
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9682
Ames testNon AMES toxic0.6085
CarcinogenicityNon-carcinogens0.8201
BiodegradationNot ready biodegradable0.978
Rat acute toxicity2.6628 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9916
hERG inhibition (predictor II)Inhibitor0.7718
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as macrolactams. These are cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. They are nitrogen analogues (the a nitrogen atom replacing the o atom of the cyclic carboxylic acid group ) of the naturally occurring macrolides.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolactams
Sub Class
Not Available
Direct Parent
Macrolactams
Alternative Parents
Proline and derivatives / Alpha amino acid amides / Beta amino acids and derivatives / Thiazolecarboxylic acids and derivatives / N-acylpyrrolidines / Pyrrolidinecarboxamides / 2-heteroaryl carboxamides / 2,4-disubstituted thiazoles / Benzene and substituted derivatives / Pyridines and derivatives
show 16 more
Substituents
Proline or derivatives / Macrolactam / Alpha-amino acid amide / Beta amino acid or derivatives / Alpha-amino acid or derivatives / 2-heteroaryl carboxamide / Pyrrolidine carboxylic acid or derivatives / Pyrrolidine-2-carboxamide / Thiazolecarboxylic acid or derivatives / N-acylpyrrolidine
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Shigella flexneri
Pharmacological action
Unknown
General Function
Translation elongation factor activity
Specific Function
This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.
Gene Name
tufA
Uniprot ID
Q83JC4
Uniprot Name
Elongation factor Tu
Molecular Weight
43283.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on June 04, 2019 05:42